1. https://spid.center/articles/419.
2. Bauer H: The Case for the Loch Ness «Monster»: The Scientific Evidence. Journal of Scientific Exploration 2002, 16(2):225—46.
3. http://visual-science.com/ru/projects/hiv/illustrations.
4. Liu J et al: 3D visualization of HIV virions by cryoelectron tomography. Methods Enzymol 2010, 483:267-90.
5. Lopalco L: CCR5: From Natural Resistance to a New Anti-HIV Strategy. Viruses 2010, 2(2):574-600.
6. Hutter G et al: Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009, 360(7):692-8.
7. Allers K et al: Evidence for the cure of HIV infection by CCR5Delta32/Delta32 stem cell transplantation. Blood 2011, 117(10):2791-9.
8. Dorr P et al: Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005, 49(11):4721-32.
9. Holt N et al: Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 2010, 28(8):839-47.
10. Perez EE et al: Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol 2008, 26(7):808-16.
11. Cornu TI et al: Editing CCR5: a novel approach to HIV gene therapy. Adv Exp Med Biol 2015, 848:117-30.
12. Kuwata T et al: Association of progressive CD4(+) T cell decline in SIV infection with the induction of autoreactive antibodies. PLoS Pathog 2009, 5(4):e1000372.
13. Juompan LY et al: Analysis of the immune responses in chimpanzees infected with HIV type 1 isolates. AIDS Res Hum Retroviruses 2008, 24(4):573-86.
14. Gallo RC, Montagnier L: The discovery of HIV as the cause of AIDS. N Engl J Med 2003, 349(24):2283-5.
15. Ratner L et al: Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 1985, 313(6000):277-84.
16. https://www.ncbi.nlm.nih.gov/nuccore/AF033819.
17. Chou R et al: Screening for HIV: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2005, 143(1):55-73.
18. Davis KR, Weller SC: The effectiveness of condoms in reducing heterosexual transmission of HIV. Fam Plann Perspect 1999, 31(6):272-9.
19. Giannou FK et al: Condom effectiveness in reducing heterosexual HIV transmission: a systematic review and meta-analysis of studies on HIV serodiscordant couples. Expert Rev Pharmacoecon Outcomes Res 2016, 16(4):489-99.
20. Ebina H et al: Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Sci Rep 2013, 3:2510.
19. Giannou FK et al: Condom effectiveness in reducing heterosexual HIV transmission: a systematic review and meta-analysis of studies on HIV serodiscordant couples. Expert Rev Pharmacoecon Outcomes Res 2016, 16(4):489-99.
20. Ebina H et al: Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Sci Rep 2013, 3:2510.
19. Giannou FK et al: Condom effectiveness in reducing heterosexual HIV transmission: a systematic review and meta-analysis of studies on HIV serodiscordant couples. Expert Rev Pharmacoecon Outcomes Res 2016, 16(4):489-99.
20. Ebina H et al: Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Sci Rep 2013, 3:2510.
19. Giannou FK et al: Condom effectiveness in reducing heterosexual HIV transmission: a systematic review and meta-analysis of studies on HIV serodiscordant couples. Expert Rev Pharmacoecon Outcomes Res 2016, 16(4):489-99.
20. Ebina H et al: Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Sci Rep 2013, 3:2510.
